(Circulation. 1995;92:1883-1890.)
© 1995 American Heart Association, Inc.
Articles |
Superficial Accumulation of Plasminogen During Plasma Clot Lysis
From Gaubius Laboratory, TNO-PG, Leiden, Netherlands.
Correspondence to Dr D.C. Rijken, Gaubius Laboratory, TNO-PG, PO Box 2215, 2301 CE Leiden, Netherlands. E-mail dc.rijken@pg.tno.nl.
Background Binding of plasminogen to partially degraded fibrin is an important step in fibrinolysis, influencing its rate and fibrin specificity. Little is known about the spatial distribution of plasminogen and of plasminogen-binding sites inside thrombi during lysis. In the present study, we investigated this problem, which is important for a better understanding of the local regulation of fibrinolysis and the rate-limiting factors of therapeutic thrombolysis.
Methods and Results An experimental system was used that allowed
continuous visualization and quantification by fluorescence
microscopy of the spatial distribution of
fluorescein-labeled plasminogen inside and
outside model thrombi. Strong superficial accumulation of
plasminogen was observed during lysis of a plasma clot
induced by tissue-type or urokinase-type plasminogen
activators in the surrounding plasma. A distinctly visible
plasminogen-accumulating shell moved continuously with the
reducing surface of the clot. The accumulation decreased in conditions
of exhaustive activation of plasminogen in the outer
plasma. It was found in a purified system that a thin superficial layer
(
50 µm wide) of a plasmin-treated fibrin clot exposes about 2.5
plasminogen-binding sites per fibrin monomer with a
Kd of 2.2 µmol/L. At a
physiological concentration of
plasminogen (1.5 µmol/L) in the outer medium,
plasminogen was concentrated about 10-fold in this layer.
The binding was dose-dependently inhibited by 
-aminocaproic
acid.
Conclusions We conclude that the generation of potent surface-associated plasminogen-binding sites during thrombolysis results in a strikingly high plasminogen concentration at the dynamically changing surface of a lysing clot. The necessity of a continuous plasminogen supply from the plasma supports the use of fibrin-specific and plasminogen-sparing agents for thrombolytic therapy.
Key Words: binding sites • plasminogen • plasminogen activators • fibrinolysis • thrombolysis
This article has been cited by other articles:
 |
|
 |
|
  B.-S. Ding, N. Hong, J.-C. Murciano, K. Ganguly, C. Gottstein, M. Christofidou-Solomidou, S. M. Albelda, A. B. Fisher, D. B. Cines, and V. R. Muzykantov Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature Blood, February 15, 2008; 111(4): 1999 - 2006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. H.C. Guimaraes, N. Laurens, E. M. Weijers, P. Koolwijk, V. W.M. van Hinsbergh, and D. C. Rijken TAFI and Pancreatic Carboxypeptidase B Modulate In Vitro Capillary Tube Formation by Human Microvascular Endothelial Cells Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2157 - 2162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Danielyan, B.-S. Ding, C. Gottstein, D. B. Cines, and V. R. Muzykantov Delivery of Anti-Platelet-Endothelial Cell Adhesion Molecule Single-Chain Variable Fragment-Urokinase Fusion Protein to the Cerebral Vasculature Lyses Arterial Clots and Attenuates Postischemic Brain Edema J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 947 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Zaitsev, K. Danielyan, J.-C. Murciano, K. Ganguly, T. Krasik, R. P. Taylor, S. Pincus, S. Jones, D. B. Cines, and V. R. Muzykantov Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood, September 15, 2006; 108(6): 1895 - 1902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-S. Ding, T. Dziubla, V. V. Shuvaev, S. Muro, and V. R. Muzykantov Advanced drug delivery systems that target the vascular endothelium. Mol. Interv., April 1, 2006; 6(2): 98 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ganguly, M. S. Goel, T. Krasik, K. Bdeir, S. L. Diamond, D. B. Cines, V. R. Muzykantov, and J.-C. Murciano Fibrin Affinity of Erythrocyte-Coupled Tissue-Type Plasminogen Activators Endures Hemodynamic Forces and Enhances Fibrinolysis in Vivo J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-S. Ding, C. Gottstein, A. Grunow, A. Kuo, K. Ganguly, S. M. Albelda, D. B. Cines, and V. R. Muzykantov Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature Blood, December 15, 2005; 106(13): 4191 - 4198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ganguly, T. Krasik, S. Medinilla, K. Bdeir, D. B. Cines, V. R. Muzykantov, and J. C. Murciano Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Lishko, V. V. Novokhatny, V. P. Yakubenko, H. V. Skomorovska-Prokvolit, and T. P. Ugarova Characterization of plasminogen as an adhesive ligand for integrins {alpha}M{beta}2 (Mac-1) and {alpha}5{beta}1 (VLA-5) Blood, August 1, 2004; 104(3): 719 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lian, S. J. Szarka, K. K. S. Ng, and S.-L. Wong Engineering of a Staphylokinase-based Fibrinolytic Agent with Antithrombotic Activity and Targeting Capability toward Thrombin-rich Fibrin and Plasma Clots J. Biol. Chem., July 11, 2003; 278(29): 26677 - 26686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Murciano, S. Muro, L. Koniaris, M. Christofidou-Solomidou, D. W. Harshaw, S. M. Albelda, D. N. Granger, D. B. Cines, and V. R. Muzykantov ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface Blood, May 15, 2003; 101(10): 3977 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.Ph. Collet, G. Montalescot, C. Lesty, and J.W. Weisel A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots Circ. Res., March 8, 2002; 90(4): 428 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Schatteman, F. Goossens, J. Leurs, R. Verkerk, S. Scharpe, J. J. Michiels, and D. Hendriks arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis Clinical and Applied Thrombosis/Hemostasis, April 1, 2001; 7(2): 93 - 101. [Abstract] [PDF]
|
|
|
|
|
|
L. Bajzar Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway Arterioscler Thromb Vasc Biol, December 1, 2000; 20(12): 2511 - 2518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Trial of Abciximab With and Without Low-Dose Reteplase for Acute Myocardial Infarction Circulation, June 20, 2000; 101(24): 2788 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Collet, D. Park, C. Lesty, J. Soria, C. Soria, G. Montalescot, and J. W. Weisel Influence of Fibrin Network Conformation and Fibrin Fiber Diameter on Fibrinolysis Speed : Dynamic and Structural Approaches by Confocal Microscopy Arterioscler Thromb Vasc Biol, May 1, 2000; 20(5): 1354 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Walker and M. E. Nesheim The Molecular Weights, Mass Distribution, Chain Composition, and Structure of Soluble Fibrin Degradation Products Released from a Fibrin Clot Perfused with Plasmin J. Biol. Chem., February 19, 1999; 274(8): 5201 - 5212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Veklich, C. W. Francis, J. White, and J. W. Weisel Structural Studies of Fibrinolysis by Electron Microscopy Blood, December 15, 1998; 92(12): 4721 - 4729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, M. B. Boffa, L. Bajzar, J. B. Walker, and M. E. Nesheim A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor J. Biol. Chem., October 16, 1998; 273(42): 27176 - 27181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Sakharov, E. F. Plow, and D. C. Rijken On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B J. Biol. Chem., May 30, 1997; 272(22): 14477 - 14482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kolev, K. Tenekedjiev, E. Komorowicz, and R. Machovich Functional Evaluation of the Structural Features of Proteases and Their Substrate in Fibrin Surface Degradation J. Biol. Chem., May 23, 1997; 272(21): 13666 - 13675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Sakharov, H. R. Lijnen, and D. C. Rijken Interactions between Staphylokinase, Plasmin(ogen), and Fibrin. STAPHYLOKINASE DISCRIMINATES BETWEEN FREE PLASMINOGEN AND PLASMINOGEN BOUND TO PARTIALLY DEGRADED FIBRIN J. Biol. Chem., November 1, 1996; 271(44): 27912 - 27918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Sakharov, J. F. Nagelkerke, and D. C. Rijken Rearrangements of the Fibrin Network and Spatial Distribution of Fibrinolytic Components during Plasma Clot Lysis J. Biol. Chem., January 26, 1996; 271(4): 2133 - 2138. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Walker and M. E. Nesheim A Kinetic Analysis of the Tissue Plasminogen Activator and DSPAalpha 1 Cofactor Activities of Untreated and TAFIa-treated Soluble Fibrin Degradation Products of Varying Size J. Biol. Chem., January 26, 2001; 276(5): 3138 - 3148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.Ph. Collet, G. Montalescot, C. Lesty, and J.W. Weisel A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots Circ. Res., March 8, 2002; 90(4): 428 - 434. [Abstract] [Full Text] [PDF]
|
|